PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/​TICO Treatment Trial)

Grandits et al., NCT05780541, NCT05780541, Feb 2024
RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
OutcomeImprovementEffect · pTreatmentControl
risk of death 21.9% higher · RR 1.22 · p = 0.77 21.9% higherRR 1.22p = 0.77 9 of 32 (28.1%) 6 of 26 (23.1%) treatment 9 of 32 (28.1%), control 6 of 26 (23.1%)day 90
risk of no hospital discharge 43.8% lower · RR 0.56 · p = 0.11 43.8% lowerRR 0.56p = 0.11 9 of 32 (28.1%) 13 of 26 (50.0%) treatment 9 of 32 (28.1%), control 13 of 26 (50.0%)NNT 4.6day 90

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Grandits et al., 9 Feb 2024, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 1 author, trial NCT05780541 (history).
Late treatment
is less effective